Valbiotis SAS (ALVAL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Valbiotis SAS (ALVAL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH2360127D
  • |
  • Pages: 34
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Valbiotis SAS (Valbiotis) is a biotechnology company that develops novel solutions to help prevent cardiometabolic diseases, besides nutrition products. It develops solutions to prevent type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity and cardiovascular diseases. The company has three products under development based on the active ingredient TOTUM-63. They include Valedia, indicated in prediabetic stage; VAL-63 NAFLD, for the treatment of NASH; and VAL-630, for the treatment of NASH and type 2 diabetes. The company's pipeline products also include Lipidrive for obesity and VAL-070 for dyslipidemia. The company has partnerships with academic centers to develop its products, besides financial support from the European Union. Valbiotis is headquartered in La Rochelle, France.

Valbiotis SAS (ALVAL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Valbiotis SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Valbiotis SAS, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Valbiotis Raises USD2.45 Million in Second Round Financing 10

Valbiotis Raises USD1.6 Million in Venture Financing 11

Partnerships 12

Valbiotis Enters into Agreement with Biofortis 12

Valbiotis Enters into Agreement with Catholic University of Louvain 13

Valbiotis, Blaise Pascal University and Laboratoire AME2P Enter into Research Agreement 14

Licensing Agreements 15

Valbiotis Enters into Option for Licensing Agreement with SATT Grand Centre 15

Equity Offering 16

Valbiotis Completes Underwriter Partial Exercise of Over-Allotment Option of IPO for USD13.7 Million 16

Valbiotis SAS-Key Competitors 17

Valbiotis SAS-Key Employees 18

Valbiotis SAS-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Strategy And Business Planning 20

Sep 06, 2017: VALBIOTIS Opens a New Clinical Investigation Center at the Institut Pasteur in Lille as Part of the Phase IIa study on Totum-63, the Active Ingredient of Valedia 20

Financial Announcements 21

Sep 29, 2017: VALBIOTIS: First Half of 2017 21

Corporate Communications 24

Oct 08, 2018: Valbiotis confirms its international expansion with the appointment of Murielle Cazaubiel, founder and former executive director of Biofortis Merieux Nutrisciences Europe 24

Aug 30, 2018: VALBOTIS strengthens its board of directors and announces the appointment of Pascal SIRVENT 26

Sep 20, 2017: International Pharmaceutical and Nutrition Expert Dr. Jean Zetlaoui Joins VALBIOTIS' Supervisory Board 27

Product News 28

Dec 04, 2017: Metformin + TOTUM-63 combination: VALBIOTIS announces first preclinical data for possible use in diabetes real life practice 28

Dec 04, 2017: Metformin + TOTUM-63 Combination: VALBIOTIS Announces First Preclinical Data for Possible Use in Diabetes Real Life Practice 29

Mar 06, 2018: VALBIOTIS: LpD64 acts on alterations of the microbiota involved in the development of obesity 30

Feb 27, 2018: VALBIOTIS completes Phase I/II clinical study recruitment for VAL-070, a product to reduce a cardiovascular risk factor 31

Other Significant Developments 32

Sep 18, 2018: VALBIOTIS expands its innovation capacity with its new Discovery and Preclinical Research platform 32

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34

List of Figures

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Valbiotis SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Valbiotis SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Valbiotis SAS, Deals By Therapy Area, 2012 to YTD 2018 8

Valbiotis SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Valbiotis Raises USD2.45 Million in Second Round Financing 10

Valbiotis Raises USD1.6 Million in Venture Financing 11

Valbiotis Enters into Agreement with Biofortis 12

Valbiotis Enters into Agreement with Catholic University of Louvain 13

Valbiotis, Blaise Pascal University and Laboratoire AME2P Enter into Research Agreement 14

Valbiotis Enters into Option for Licensing Agreement with SATT Grand Centre 15

Valbiotis Completes Underwriter Partial Exercise of Over-Allotment Option of IPO for USD13.7 Million 16

Valbiotis SAS, Key Competitors 17

Valbiotis SAS, Key Employees 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Valbiotis SAS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17250
Site License
USD 500 INR 34500
Corporate User License
USD 750 INR 51750

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com